- Home
- GHY vs IMTX Comparison
GHY vs IMTX Comparison
Compare GHY & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- IMTX
- Stock Information
- Founded
- GHY 2012
- IMTX N/A
- Country
- GHY United States
- IMTX Germany
- Employees
- GHY N/A
- IMTX N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GHY Finance
- IMTX Health Care
- Exchange
- GHY Nasdaq
- IMTX Nasdaq
- Market Cap
- GHY 548.8M
- IMTX 653.9M
- IPO Year
- GHY N/A
- IMTX N/A
- Fundamental
- Price
- GHY $13.27
- IMTX $5.69
- Analyst Decision
- GHY
- IMTX Strong Buy
- Analyst Count
- GHY 0
- IMTX 4
- Target Price
- GHY N/A
- IMTX $14.67
- AVG Volume (30 Days)
- GHY 184.8K
- IMTX 572.9K
- Earning Date
- GHY 01-01-0001
- IMTX 08-13-2025
- Dividend Yield
- GHY 10.58%
- IMTX N/A
- EPS Growth
- GHY N/A
- IMTX N/A
- EPS
- GHY N/A
- IMTX N/A
- Revenue
- GHY N/A
- IMTX $152,823,253.00
- Revenue This Year
- GHY N/A
- IMTX N/A
- Revenue Next Year
- GHY N/A
- IMTX $1.92
- P/E Ratio
- GHY N/A
- IMTX N/A
- Revenue Growth
- GHY N/A
- IMTX 83.61
- 52 Week Low
- GHY $10.24
- IMTX $3.30
- 52 Week High
- GHY $11.92
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- GHY 54.57
- IMTX 41.21
- Support Level
- GHY $12.96
- IMTX $5.42
- Resistance Level
- GHY $13.35
- IMTX $6.47
- Average True Range (ATR)
- GHY 0.09
- IMTX 0.36
- MACD
- GHY 0.00
- IMTX -0.11
- Stochastic Oscillator
- GHY 64.82
- IMTX 21.77
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.